Introduction {#H1-1-YOI180080}
============

A diagnosis of cancer can cause substantial psychological distress.^[@yoi180080r1]^ Patients may fear death; pain; adverse effects of treatment, such as disfigurement or loss of function; or alterations in their family and community roles.^[@yoi180080r1]^ This distress may have a role in the development of suicide ideation: previous evidence from systematic reviews has shown an increased risk of suicide among patients with cancer.^[@yoi180080r2],[@yoi180080r3]^

In the United Kingdom, the prevalence of patients with a cancer diagnosis is growing, driven by increased survival, improved cancer treatments, and expanding cancer screening programs.^[@yoi180080r4]^ Despite political and financial prioritization of diagnostic and therapeutic cancer services and public health campaigns aimed at facilitating earlier diagnosis of cancer, there are substantial historical resource constraints for mental health services. In addition, acute care hospitals and mental health services remain disconnected.^[@yoi180080r5],[@yoi180080r6]^

Although the absolute risk of suicide may be low compared with the risks for other causes of death in patients with cancer, these deaths are potentially preventable. They are also a proxy marker of substantial psychological distress in patients with cancer. In 2015, the Cancer Taskforce report highlighted that better management of depression could improve patient outcomes, affecting quality of life as well as adherence to treatment, thereby having an influence on survival.^[@yoi180080r7]^ To target psychological screening and support for the patients in greatest psychological distress and at risk of suicide, we need to understand variation in risk of suicide by patient group as defined by, for example, age, sex, and cancer type.

To our knowledge, this study is the first national population-level analysis of suicide among patients with cancer in England. Using longitudinal data from the National Cancer Registration and Analysis Service, linked to Office for National Statistics death certification data, we examined the risk of suicide in patients with a cancer diagnosis compared with that of the general population. We further analyzed the risk in terms of cancer type and stage, time since diagnosis, and sociodemographic factors.

Methods {#H1-2-YOI180080}
=======

Study Population {#H2-1-YOI180080}
----------------

Patients diagnosed with a malignant tumor (*International Statistical Classification of Diseases*, *10th Revision \[ICD-10\]* codes C00-C97, excluding C44, nonmelanoma skin cancer, using an internal mapping system for all *ICD* revisions) during January 1, 1995, to December 31, 2015, and aged 18 to 99 years at diagnosis, were identified from Public Health England's national cancer registration database. All patients were residents of England at the time of their diagnosis. Patients identified as having cancer on their death certificate alone were excluded as these patients were not aware of their diagnosis. Individuals diagnosed on the same day as their death contributed 1 day to the risk period. For individuals with more than 1 cancer diagnosis, the date and diagnosis of their most recent cancer was selected using the groupings available in eTable 1 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}. The study was exempt from gaining individual consent to participate having obtained approval from the UK Patient Information Advisory Group (now the Confidentiality Advisory Group, under Section 251 of the National Health Service Act 2006 \[PIAG 03(a)/2001\]). Ethical approval was not applicable.

Cause of death was ascertained through tracing by the Office for National Statistics. All deaths in patients with cancer that received a verdict of suicide or an open verdict at the inquest were selected. An open verdict is a legal decision that records a death, but does not state the cause. These were identified using *ICD-10* codes for suicide (X60-X84 and Y87.0) and open verdicts (Y10-Y34 \[excluding Y33.9, which is now called U309\] and Y87.2 \[event of undetermined intent\]) and their *International Classification of Diseases, Ninth Revision (ICD-9)*equivalents: E950-E959 for suicide and self-inflicted injury and E980-E989 (excluding E988.8) for undetermined death. Deaths were selected using the final underlying cause of death, as per the World Health Organization guidelines.^[@yoi180080r8]^

The income deprivation quintile was derived by linking each patient's postcode at diagnosis (at the Lower Super Output Area geography) to the income domain of the Index of Multiple Deprivation.^[@yoi180080r9]^ Equal population quintiles were derived across England from the income domain score, and each patient with cancer was assigned the income deprivation quintile of their local geography. Ethnicity was self-reported, recorded in hospital patient administration systems, and submitted to the cancer registry. If a patient's ethnicity was unknown, it was supplemented by information on self-reported ethnicity as recorded in the Hospital Episode Statistics data set. As ethnicity may be recorded differently during each hospital admission, the modal value was used in cases of discrepancy, preferring the most recent ethnicity documented in the event of a tied modal value.

The cancer registry operates on a benchmark of 70% completeness for stage. Completeness of stage has been deemed sufficient for analysis since 2012^[@yoi180080r10]^; thus, stage at cancer diagnosis was selected for a subgroup analysis.

Statistical Analysis {#H2-2-YOI180080}
--------------------

Each patient was entered into the analysis on their date of cancer diagnosis and was censored at the date of death, date when lost to follow-up, or August 31, 2017. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated using standard cohort techniques.^[@yoi180080r11]^ The SMR was defined as the number of deaths by suicide observed in the cancer population / number of expected deaths by suicide. The AER was defined as the (\[number observed − number expected\] / \[person-years at risk\]) × 10 000. These measures estimate the proportional increase in the suicide rate compared with rates in the general population and the absolute excess suicide rate compared with the general population, respectively. Population-based expected deaths were derived from age (5-year groups), sex, and calendar-year (1-year groups) specific death rates for England.^[@yoi180080r12]^

Tests for heterogeneity were performed using likelihood ratio tests based on Poisson regression models. This test compared the deviance of a model including the factor of interest to the deviance of a model without the factor of interest. Statistical significance was defined as 2-sided with significance level set at *P* \< .05.

Multivariable Poisson regression models were used to evaluate the simultaneous effect of the factors of interest. All factors were fitted in the regression model with no interaction terms. These factors were sex, cancer type, deprivation, race/ethnicity, age at cancer diagnosis, year of diagnosis, attained age, and follow-up period. Attained age and follow-up period were never fitted in the same model due to strong collinearity. These multivariable models produced relative risks (with an offset of the log of the expected number of deaths), which were the ratio of SMRs adjusted for all factors, and relative excess risks (with an offset of the log of the person-years and a link function^[@yoi180080r13]^), which were the ratio of AERs adjusted for all factors.^[@yoi180080r11]^ The heterogeneity tests from the multivariable models are presented herein, and the estimates are presented in eTable 2 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}. All calculations were performed using Stata, version 13 (StataCorp).

Results {#H1-3-YOI180080}
=======

Patient Characteristics and Overall Findings {#H2-3-YOI180080}
--------------------------------------------

A total of 4 722 099 individuals (50.3% men and 49.7% women) aged 18 to 99 years received a diagnosis of cancer during the study period. A total of 3 509 392 patients in the cohort (74.3%) were aged 60 years or older at the time of diagnosis. A total of 2491 patients (1719 men and 772 women) with cancer were recorded to have died by suicide over a follow-up period up to 22 years. This number represented 0.08% of all deaths. The cohort characteristics are summarized in [Table 1](#yoi180080t1){ref-type="table"}. The cohort contributed a total of 22 036 669 person-years, and the mean (SD) and median follow-up were 4.67 (5.33) and 2.52 years, respectively. The SMR for all cancers combined was 1.20 (95% CI, 1.16-1.25) and the AER per 10 000 person-years at risk was 0.19 (95% CI, 0.15-0.23) ([Table 2](#yoi180080t2){ref-type="table"}). An elevated risk was demonstrated in each deprivation quintile, where no significant heterogeneity was observed ([Table 3](#yoi180080t3){ref-type="table"}). There were variations in the association between suicide risk and attained age, with significant heterogeneity overall ([Table 3](#yoi180080t3){ref-type="table"} and eTable 3 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}).

###### Characteristics of Study Cohort

  Characteristic                          Patients With Cancer, No.   Deaths                      
  --------------------------------------- --------------------------- -------- ----------- ------ -------
  Total                                   4 722 099                   2491     3 078 843   0.08   
  Sex                                                                                             
  Male                                    2 376 908                   1719     1 652 298   0.10   69.01
  Female                                  2 345 191                   772      1 426 545   0.05   30.99
  Time from cancer diagnosis                                                                      
  0-5 mo                                  1 253 682                   540      1 238 800   0.04   21.68
  6-11 mo                                 398 010                     241      396 936     0.06   9.67
  12-23 mo                                487 700                     329      430 204     0.08   13.21
  24-35 mo                                394 513                     261      234 198     0.11   10.48
  3-4 y                                   556 897                     316      274 653     0.12   12.69
  5-9 y                                   846 352                     521      323 021     0.16   20.92
  ≥10 y                                   784 945                     283      181 031     0.16   11.36
  Age at death (attained age), y                                                                  
  18-29                                   19 271                      15       8260        0.18   0.60
  30-49                                   265 245                     267      114 831     0.23   10.72
  50-59                                   493 004                     422      259 911     0.16   16.94
  60-69                                   956 714                     585      578 161     0.10   23.48
  70-79                                   1 451 587                   647      954 159     0.07   25.97
  ≥80                                     1 536 278                   555      1 163 521   0.05   22.28
  Last primary cancer                                                                             
  Bladder                                 172 359                     120      127 291     0.09   4.82
  Breast                                  744 817                     339      293 606     0.12   13.61
  Cancer of unknown primary               177 747                     29       170 004     0.02   1.16
  CNS (including brain)                   70 906                      28       62 276      0.04   1.12
  Cervix                                  50 696                      23       20 258      0.11   0.92
  Colorectal                              578 270                     349      392 959     0.09   14.01
  Head and neck                           167 307                     176      89 713      0.20   7.07
  Hodgkin lymphoma                        25 155                      25       7307        0.34   1.00
  Kidney and unspecified urinary organs   122 974                     72       78 693      0.09   2.89
  Leukemia                                116 707                     53       82 239      0.06   2.13
  Liver                                   51 800                      10       47 900      0.02   0.40
  Lung                                    613 772                     184      577 911     0.03   7.39
  Melanoma                                161 734                     97       49 808      0.19   3.89
  Mesothelioma                            36 062                      20       35 059      0.06   0.80
  Multiple myeloma                        73 191                      41       55 836      0.07   1.65
  Non-Hodgkin lymphoma                    170 764                     113      101 264     0.11   4.54
  Esophagus                               122 132                     57       111 553     0.05   2.29
  Other malignant neoplasms               133 186                     78       93 364      0.08   3.13
  Ovary                                   112 384                     33       76 763      0.04   1.32
  Pancreas                                121 207                     33       117 298     0.03   1.32
  Prostate                                594 521                     444      302 584     0.15   17.82
  Sarcoma                                 28 712                      14       15 951      0.09   0.56
  Stomach                                 128 965                     59       117 763     0.05   2.37
  Testis                                  34 630                      58       2835        2.05   2.33
  Uterus                                  112 101                     36       48 608      0.07   1.45
  Deprivation                                                                                     
  1, Least                                922 123                     505      533 157     0.09   20.27
  2                                       999 928                     558      620 458     0.09   22.40
  3                                       984 525                     518      645 294     0.08   20.79
  4                                       940 242                     492      648 231     0.08   19.75
  5, Most                                 875 281                     418      631 703     0.07   16.78
  Race/ethnicity                                                                                  
  White                                   3 087 922                   1521     1 913 960   0.08   61.06
  Mixed                                   7654                        5        3090        0.16   0.20
  Asian                                   55 955                      16       26 007      0.06   0.64
  Black                                   46 039                      11       22 213      0.05   0.44
  Other                                   35 148                      19       18 247      0.10   0.76
  Not stated                              703 527                     435      535 181     0.08   17.46
  Unknown                                 785 854                     484      560 145     0.09   19.43
  Age at cancer diagnosis, y                                                                      
  18-29                                   63 059                      49       12 048      0.41   1.97
  30-49                                   465 201                     368      151 316     0.24   14.77
  50-59                                   684 447                     492      318 169     0.15   19.75
  60-69                                   1 167 097                   630      676 827     0.09   25.29
  70-79                                   1 354 726                   624      1 032 533   0.06   25.05
  ≥80                                     987 569                     328      887 950     0.04   13.17
  Year of cancer diagnosis                                                                        
  1995-1999                               995 756                     486      836 543     0.06   19.51
  2000-2004                               1 056 151                   736      795 971     0.09   29.55
  2005-2009                               1 149 793                   681      734 519     0.09   27.34
  2010-2015                               1 520 399                   588      711 810     0.08   23.60

Abbreviation: CNS, central nervous system.

###### Suicide SMRs and AERs per 10 000 Person-Years at Risk According to Last Primary Cancer

  Last Primary Cancer                                                                                   Observed/Expected   SMR (95% CI)          AER per 10 000 (95% CI)
  ----------------------------------------------------------------------------------------------------- ------------------- --------------------- -------------------------
  Total                                                                                                 2491/2072           1.20 (1.16 to 1.25)   0.19 (0.15 to 0.23)
  **Significantly Increased Suicide Rate Among Patients With Cancers vs General Population**                                                      
  Mesothelioma                                                                                          20/4                4.51 (2.91 to 7.00)   4.20 (1.84 to 6.57)
  Pancreas                                                                                              33/8                3.89 (2.77 to 5.48)   2.89 (1.56 to 4.22)
  Esophagus                                                                                             57/22               2.65 (2.04 to 3.43)   1.83 (1.07 to 2.60)
  Lung                                                                                                  184/72              2.57 (2.23 to 2.97)   1.56 (1.19 to 1.93)
  Stomach                                                                                               59/27               2.20 (1.71 to 2.84)   1.35 (0.72 to 1.98)
  Cancer of unknown primary                                                                             29/15               1.98 (1.38 to 2.85)   1.00 (0.26 to 1.74)
  Head and neck                                                                                         176/105             1.67 (1.44 to 1.94)   0.74 (0.46 to 1.01)
  CNS (including brain)                                                                                 28/17               1.61 (1.11 to 2.33)   0.74 (0.01 to 1.48)
  Multiple myeloma                                                                                      41/26               1.57 (1.15 to 2.13)   0.58 (0.09 to 1.08)
  Other malignant neoplasms                                                                             78/54               1.46 (1.17 to 1.82)   0.44 (0.13 to 0.76)
  Colorectal                                                                                            349/274             1.28 (1.15 to 1.42)   0.28 (0.14 to 0.41)
  **Significantly Increased Proportional SMR Among Patients With Cancers vs General Population**                                                  
  Non-Hodgkin lymphoma                                                                                  113/93              1.22 (1.01 to 1.47)   0.23 (−0.01 to 0.46)
  **Significantly Decreased Suicide Rate Among Patients With Cancers vs General Population**                                                      
  Prostate                                                                                              444/494             0.90 (0.82 to 0.99)   −0.14 (−0.25 to −0.02)
  Melanoma                                                                                              97/121              0.80 (0.66 to 0.98)   −0.20 (−0.35 to −0.04)
  **No Significant Difference in the Suicide Rate Among Patients With Cancers vs General Population**                                             
  Liver                                                                                                 10/6                1.56 (0.84 to 2.90)   0.64 (−0.47 to 1.75)
  Ovary                                                                                                 33/27               1.23 (0.87 to 1.73)   0.12 (−0.10 to 0.34)
  Kidney and unspecified urinary organs                                                                 72/59               1.22 (0.96 to 1.53)   0.24 (−0.07 to 0.55)
  Bladder                                                                                               120/106             1.13 (0.95 to 1.36)   0.16 (−0.08 to 0.41)
  Breast                                                                                                339/313             1.08 (0.97 to 1.21)   0.04 (−0.02 to 0.11)
  Cervix                                                                                                23/22               1.05 (0.69 to 1.57)   0.03 (−0.22 to 0.27)
  Leukemia                                                                                              53/52               1.02 (0.78 to 1.34)   0.02 (−0.28 to 0.32)
  Hodgkin lymphoma                                                                                      25/26               0.95 (0.64 to 1.41)   −0.06 (−0.52 to 0.40)
  Uterus                                                                                                36/39               0.92 (0.67 to 1.28)   −0.04 (−0.19 to 0.11)
  Testis                                                                                                58/71               0.81 (0.63 to 1.05)   −0.36 (−0.76 to 0.04)
  Sarcoma                                                                                               14/18               0.77 (0.45 to 1.30)   −0.26 (−0.72 to 0.19)
  *P* value for heterogeneity                                                                                               \<.001                \<.001
  Adjusted (follow-up) *P* value for heterogeneity[^a^](#yoi180080t2n1){ref-type="table-fn"}                                \<.001                \<.001

Abbreviations: AERs, absolute excess risks; CNS, central nervous system; SMRs, standardized mortality ratios.

Fully adjusted for sex, cancer type, deprivation, race/ethnicity, age at cancer diagnosis, year of diagnosis (5-year groups), and follow-up period.

###### Suicide SMRs and AERs per 10 000 Person-Years at Risk According to Key Patient Characteristics for All Cancers Combined[^a^](#yoi180080t3n1){ref-type="table-fn"}

  Characteristic                                                                                  Observed/Expected   SMR (95% CI)                                                    AER per 10 000 (95% CI)
  ----------------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------- ----------------------------------------------------------------
  Sex                                                                                                                                                                                 
  Men                                                                                             1719/1433           1.20 (1.14 to 1.26)                                             0.29 (0.21 to 0.37)
  Women                                                                                           772/639             1.21 (1.13 to 1.30)                                             0.11 (0.06 to 0.15)
  *P* value for heterogeneity                                                                                         .88                                                             \<.001
  Adjusted (follow-up) *P* value for heterogeneity[^b^](#yoi180080t3n2){ref-type="table-fn"}                          .52                                                             \<.001
  Age at death (attained age), y                                                                                                                                                      
  18-29                                                                                           15/22               0.69 (0.42 to 1.15)                                             −0.30 (−0.64 to 0.05)
  30-49                                                                                           267/268             1.00 (0.88 to 1.12)                                             0.00 (−0.14 to 0.13)
  50-59                                                                                           422/348             1.21 (1.10 to 1.33)                                             0.22 (0.10 to 0.34)
  60-69                                                                                           585/447             1.31 (1.21 to 1.42)                                             0.25 (0.16 to 0.33)
  70-79                                                                                           647/502             1.29 (1.19 to 1.39)                                             0.24 (0.15 to 0.32)
  ≥80                                                                                             555/485             1.15 (1.05 to 1.24)                                             0.16 (0.06 to 0.27)
  *P* value for heterogeneity                                                                                         \<.001                                                          .01
  Adjusted (attained age) *P* value for heterogeneity[^c^](#yoi180080t3n3){ref-type="table-fn"}                       \<.001                                                          \<.001
  Deprivation                                                                                                                                                                         
  1, Least                                                                                        505/464             1.09 (1.00 to 1.19)                                             0.08 (−0.01 to 0.17)
  2                                                                                               558/466             1.20 (1.10 to 1.30)                                             0.18 (0.09 to 0.28)
  3                                                                                               518/431             1.20 (1.10 to 1.31)                                             0.19 (0.09 to 0.29)
  4                                                                                               492/384             1.28 (1.17 to 1.40)                                             0.27 (0.16 to 0.37)
  5, Most                                                                                         418/327             1.28 (1.16 to 1.41)                                             0.27 (0.15 to 0.38)
  *P* value for heterogeneity                                                                                         .07                                                             .06
  Adjusted (follow-up) *P* value for heterogeneity[^b^](#yoi180080t3n2){ref-type="table-fn"}                          .32                                                             .43
  Race/ethnicity                                                                                                                                                                      
  White                                                                                           1521/1369           1.11 (1.06 to 1.17)                                             0.10 (0.05 to 0.16)
  Mixed                                                                                           5/4                 1.38 (0.57 to 3.31)[^d^](#yoi180080t3n4){ref-type="table-fn"}   0.37 (−0.81 to 1.55)[^d^](#yoi180080t3n4){ref-type="table-fn"}
  Asian                                                                                           16/26               0.62 (0.38 to 1.01)                                             −0.36 (−0.65 to −0.07)
  Black                                                                                           11/24               0.45 (0.25 to 0.81)                                             −0.57 (−0.85 to −0.29)
  Other                                                                                           19/16               1.16 (0.74 to 1.82)                                             0.15 (−0.34 to 0.64)
  Not stated                                                                                      435/309             1.41 (1.28 to 1.55)                                             0.39 (0.26 to 0.52)
  Unknown                                                                                         484/324             1.49 (1.37 to 1.63)                                             0.46 (0.34 to 0.59)
  *P* value for heterogeneity                                                                                         \<.001                                                          \<.001
  Adjusted (follow-up) *P* value for heterogeneity[^b^](#yoi180080t3n2){ref-type="table-fn"}                          \<.001                                                          \<.001

Abbreviations: AER, absolute excess risk; CNS, central nervous system; SMR, standardized mortality ratio.

Sex, follow-up period, age at death, deprivation, and ethnicity.

Fully adjusted for sex, cancer type, deprivation, race/ethnicity, age at cancer diagnosis, year of diagnosis, and follow-up period.

Fully adjusted for sex, cancer type, deprivation, ethnicity, age at cancer diagnosis, year of diagnosis, and attained age (age at death).

Estimate is based on a low number (\<10) of observed events, and must be interpreted with caution.

Variation in Suicide Risk by Last Primary Cancer {#H2-4-YOI180080}
------------------------------------------------

There was evidence of heterogeneity by cancer type for both SMRs and AERs ([Table 2](#yoi180080t2){ref-type="table"}). This finding remained after adjustment for all factors of interest. The highest SMR and AER were observed among patients with mesothelioma, with a 4.51-fold risk compared with the general population, which corresponded to 4.20 extra deaths per 10 000 person-years. This risk was followed by pancreatic (SMR, 3.89; 95% CI, 2.77-5.48), esophageal (SMR, 2.65; 95% CI, 2.04-3.43), lung (SMR, 2.57; 95% CI, 2.23-2.97), and stomach (SMR, 2.20; 95% CI, 1.71-2.84) cancers. These excess risks resulted in between 1.35 and 2.89 extra deaths per 10 000 person-years for each cancer type. Patients with 6 further cancer types (including other malignant neoplasms) experienced a significantly increased risk of suicide in both absolute and relative terms. In contrast, patients with melanoma and prostate cancer had a significantly reduced risk of death by suicide compared with the general population.

Variation in Suicide Risk by Sex {#H2-5-YOI180080}
--------------------------------

There were more than double the number of men who died by suicide compared with women ([Table 1](#yoi180080t1){ref-type="table"}). The association with sex varied by cancer type and was greater when expressed in AERs ([Table 4](#yoi180080t4){ref-type="table"}, eTable 4 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}). The AER for men was significantly greater than for women for 6 cancer types, namely, pancreas (men, 4.41; women, 1.37), esophagus (men, 2.40; women, 0.72), lung (men, 2.15; women, 0.86), stomach (men, 2.11; women, −0.05), head and neck (men, 1.08; women, 0.29), and colorectal (men, 0.47; women, 0.05). Significant heterogeneity (*P* = .03) was observed in the SMRs by sex among patients with stomach cancer (men, 2.46; women, 0.91).

###### Suicide SMRs and AERs per 10 000 Person-Years at Risk According to Last Primary Cancer and Sex for the Primary Cancer Groupings With a Significantly Elevated SMR, Excluding Other Malignant Neoplasms[^a^](#yoi180080t4n1){ref-type="table-fn"}

  Last Primary Cancer         Sex                                                                                                                                                                                    
  --------------------------- --------------------- ----------------------------------------------------------------- ----- ---------------------- ----------------------------------------------------------------- --------
  Mesothelioma                3.95 (2.42 to 6.45)   10.53 (3.95 to 28.05)[^b^](#yoi180080t4n2){ref-type="table-fn"}   .11   4.04 (1.39 to 6.70)    4.82 (−0.40 to 10.04)[^b^](#yoi180080t4n2){ref-type="table-fn"}   .79
  Pancreas                    3.99 (2.70 to 5.90)   3.62 (1.81 to 7.23)[^b^](#yoi180080t4n2){ref-type="table-fn"}     .81   4.41 (2.10 to 6.72)    1.37 (0.06 to 2.68)[^b^](#yoi180080t4n2){ref-type="table-fn"}     .02
  Esophagus                   2.69 (2.03 to 3.56)   2.41 (1.21 to 4.82)[^b^](#yoi180080t4n2){ref-type="table-fn"}     .77   2.40 (1.33 to 3.47)    0.72 (−0.13 to 1.57)[^b^](#yoi180080t4n2){ref-type="table-fn"}    .02
  Lung                        2.53 (2.14 to 2.99)   2.72 (2.03 to 3.64)                                               .68   2.15 (1.56 to 2.75)    0.86 (0.46 to 1.26)                                               \<.001
  Stomach                     2.46 (1.89 to 3.20)   0.91 (0.34 to 2.42)[^b^](#yoi180080t4n2){ref-type="table-fn"}     .03   2.11 (1.17 to 3.05)    −0.05 (−0.52 to 0.42)[^b^](#yoi180080t4n2){ref-type="table-fn"}   \<.001
  Cancer of unknown primary   1.79 (1.14 to 2.81)   2.47 (1.33 to 4.59)                                               .42   1.23 (−0.02 to 2.48)   0.79 (−0.03 to 1.61)                                              .56
  Head and neck               1.70 (1.45 to 2.01)   1.54 (1.10 to 2.15)                                               .58   1.08 (0.65 to 1.50)    0.29 (0.01 to 0.56)                                               .002
  CNS (including brain)       1.50 (0.98 to 2.30)   2.04 (0.97 to 4.29)[^b^](#yoi180080t4n2){ref-type="table-fn"}     .49   0.88 (−0.25 to 2.01)   0.57 (−0.26 to 1.40)[^b^](#yoi180080t4n2){ref-type="table-fn"}    .67
  Multiple myeloma            1.42 (0.99 to 2.05)   2.08 (1.18 to 3.67)                                               .28   0.61 (−0.14 to 1.36)   0.55 (−0.05 to 1.15)                                              .90
  Colorectal                  1.33 (1.18 to 1.50)   1.09 (0.86 to 1.38)                                               .13   0.47 (0.25 to 0.70)    0.05 (−0.09 to 0.18)                                              .001

Abbreviations: AER, absolute excess risk; CNS, central nervous system; SMR, standardized mortality ratio.

Observed and expected values are available in eTable 4 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}.

Estimate is based on a low number (\<10) of observed events and must be interpreted with caution.

Variation in Suicide Risk by Years Since Cancer Diagnosis {#H2-6-YOI180080}
---------------------------------------------------------

The SMR was greatest in the first 6 months after cancer diagnosis (SMR, 2.74; 95% CI, 2.52-2.98; AER, 1.77; 95% CI, 1.54-2.01), but remained elevated throughout the first 3 years (2-year SMR, 1.14; 95% CI, 1.01-1.28; AER, 0.13; 95% CI, 0.00-0.27). The risk decreased over time (*P* \< .001). This association remained after multivariable adjustment ([Figure](#yoi180080f1){ref-type="fig"}, eTable 5 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}). The association with years since cancer diagnosis varied by cancer type, although there was a significantly increased risk in the first 6 months for all cancer types with an overall increased risk of suicide (eTable 4 and eTable 6 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}). Patients with mesothelioma had the highest risk of suicide in the first 6 months after diagnosis, with an 8.61-fold risk compared with the general population, corresponding to 9.36 extra deaths per 10 000 person-years at risk.

![Suicide Standardized Mortality Ratios (SMRs) and Absolute Excess Risks (AERs) per 10 000 Person-Years at Risk by Follow-up Period\
Estimates of SMRs (A) and AERs (B) are presented in eTable 5 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}. Error bars indicate 95% CIs.](jamapsychiatry-76-51-g001){#yoi180080f1}

Cumulative Risk of Suicide Mortality by Attained Age {#H2-7-YOI180080}
----------------------------------------------------

The cumulative risk of suicide mortality was greatest for patients with mesothelioma, stomach, and lung cancer. By age 80 years, the cumulative risk was 1.60% for patients with mesothelioma. The corresponding expected cumulative mortality by this age was 0.63% (eFigure in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}).

Subgroup Analyses of Suicide Risk {#H2-8-YOI180080}
---------------------------------

Among patients with cancer diagnosed since 2012, significant heterogeneity was found by stage at diagnosis (*P* \< .001) (eTable 7 in the [Supplement](#note-YOI180080-1-s){ref-type="supplementary-material"}). The SMR and AER were greatest for those with stage IV disease (SMR, 2.79; 95% CI, 2.24-3.47; AER, 1.97; 95% CI, 1.30-2.65).

Discussion {#H1-4-YOI180080}
==========

In our nationwide population-based study of 4 722 099 patients, we found that being diagnosed with cancer in England confers a 20% increased risk of suicide compared with the general population, equivalent to 0.08% of all deaths among patients with cancer or 2491 potentially preventable deaths over this period. Our study identified specific factors characterizing those at higher risk, which will assist in the needs-based psychological assessment of these groups. Cancer types associated with particularly elevated risks are mesothelioma, pancreatic, lung, esophageal, and stomach cancers. These tend to be characterized by poor prognosis. We identified the first 6 months after a cancer diagnosis to be the period of highest risk. Although suicide is hard to predict, these findings indicate that all patients, and particularly those with the cancer types at highest risk, require improved psychological support and screening for suicidality in the immediate aftermath of cancer diagnosis.

In our cohort, we found only borderline differences by level of deprivation. Although deprivation is commonly understood to be an area-level risk factor for suicide, this is not a consistent association, and the divergent findings are likely to be explained by the size of the area of aggregation.^[@yoi180080r14]^

Findings in the Context of Other Studies {#H2-9-YOI180080}
----------------------------------------

A number of studies have found an elevated risk of suicide in patients with cancer, in settings such as England, Finland, Sweden, Italy, Estonia, Japan, Norway, and the United States.^[@yoi180080r15]^ Our findings are consistent with a previous analysis of local cancer registry data in England^[@yoi180080r16]^ and European studies reported comparable SMRs, with similar high-risk clinical and demographic groups identified.^[@yoi180080r17],[@yoi180080r18]^ However, an analysis of English primary care data found no elevated risk of suicide in patients with cancers overall or in men, but a 3-fold elevated risk of suicide in women, which was independent of clinical depression.^[@yoi180080r19]^ The explanation for this apparent inconsistency in English findings may be that their data were derived from patients in 224 general physician practices, rather than our population coverage, with the validity of diagnoses reliant on quality and completeness of primary care physician records.^[@yoi180080r20]^

The findings of cancer-specific analyses concur with ours in that patients with poor prognosis tend to be those at highest risk.^[@yoi180080r16]^ More generally, the evidence suggests that suicide risk is associated with cancers with low survival rates^[@yoi180080r17]^ and limited treatment options.^[@yoi180080r15]^

We found that cancer risk varies by time since diagnosis, and the time bands that we chose suggested that suicide risk is highest in the first 6 months after diagnosis. Other studies have investigated differing time periods, but all found an elevated risk in the initial period defined after diagnosis, whether the first week,^[@yoi180080r21]^ first month,^[@yoi180080r22]^ or first year.^[@yoi180080r16]^

Strengths and Limitations {#H2-10-YOI180080}
-------------------------

To our knowledge, this study is the first to investigate suicide risk in patients with cancer with entire population-based coverage in England. This strength should support responsive service provision in England. The advantages of complete cause of death ascertainment, national coverage, and precise diagnostic information reduced the biases introduced by missing data. Nevertheless, we acknowledge the limitation of the potential for underreporting of suicide as a cause of death.^[@yoi180080r23]^ This lower level of reporting may affect data on patients with cancer more than the general population, with this bias therefore potentially underestimating the overall risk of suicide among patients with cancer.

Long-term follow-up over 22 million person-years at risk provided robust estimates of how risk varies by time since diagnosis. Tight definition of time periods clarified that risk concentrates within the first 6 months, providing more fine-grained risk information than the previous analysis of local English cancer registry data.^[@yoi180080r16]^

The inclusion of race/ethnicity in cancer registry data allowed us to present the variation in suicide risk by race/ethnicity, unlike national suicide reports.^[@yoi180080r12]^ Because the method of standardization could not include race/ethnicity, the observed trends are likely to reflect those in the general population. Given the extent of our population coverage, our findings provide the most representative description of race/ethnicity variation in suicide risk nationally, albeit with 32% missing data. Standardization was also not possible by deprivation quintile.

One limitation of the study is that it was not possible, due to current data availability, to adjust for preexisting psychiatric disorders or other potential confounders, such as alcohol or drug misuse diagnostic information. However, it has been demonstrated in a study of national cancer registration data that suicide risk is not explained by preexisting psychiatric conditions.^[@yoi180080r21]^

An additional limitation is that, because of the small numbers of deaths, we were unable to perform multivariable regression models for specific cancer types or for the subgroup analysis to assess whether the trends observed could be explained by distributional differences in other variables measured. However, our multivariable model for all cancers combined suggested that variation in the patient characteristics were not explained by differences in the other variables, including cancer type.

Clinical and Policy Implications {#H2-11-YOI180080}
--------------------------------

Clinically, our results identify specific cancers associated with significantly elevated risk of suicide and the first 6 months after diagnosis as being a critical period requiring greater vigilance for psychological distress and potential suicidality. The combined literature suggests that the first week after diagnosis has the highest risk for suicide, falling thereafter. This early phase is clearly a critical period. The mechanisms of suicide among patients with cancer are likely to be heterogeneous, involving factors beyond diagnosable psychiatric disorder. The shock of a cancer diagnosis and the losses inherent to it may be processed as a psychological threat. In some cases this shock can give rise to psychological symptoms diagnosable as depression or anxiety. The prevalence of major depression in patients with cancers is 15%,^[@yoi180080r24]^ exceeding the 2% reported for the general population.^[@yoi180080r25]^ However, as diagnostic criteria for depression rely on at least 2 weeks of pervasive low mood, patients who attempt suicide within a week of a cancer diagnosis may have been depressed for some time^[@yoi180080r26]^ or enacting a catastrophic reaction to a negative life event.^[@yoi180080r27]^

Specific cancers may present insidiously with depressed mood and certain treatments for cancer can also cause depression through their direct neuropsychiatric effects.^[@yoi180080r1]^ Awareness of the potential for such biological effects, impulsive catastrophic reactions to diagnosis, and incident or worsening depression are starting points for early identification of suicidal distress.

Predicting suicide is difficult, and most people identified as high risk for suicide do not die by suicide.^[@yoi180080r28]^ English patients with cancer have a low ratio of self-harm events to suicides compared with those for other physical and psychiatric disorders^[@yoi180080r29]^ and the general population,^[@yoi180080r30]^ presenting fewer early warning signs for suicide and limiting opportunities for intervention. Nevertheless, our findings identify the timeframe over which health professionals should ensure better monitoring of the psychological health of all patients with cancer, and particularly those with poor prognoses, and address modifiable risk factors, such as pain, substance use disorders, and psychiatric illness. Efforts to address the underdiagnosis and undertreatment of depression and anxiety in patients with cancer are likely to reap benefits in terms of reducing suicide risk, as well as positively influencing quality of life, treatment adherence, and treatment costs.^[@yoi180080r1]^ Models that integrate psychological support into cancer care, specifically collaborative screening and treatment, have shown benefits in terms of reduced depression, anxiety, and pain, even if they lack evidence for survival benefits.^[@yoi180080r31]^

Access to the means of suicide may influence risk, and restricting access is the suicide prevention intervention with the best evidence for effectiveness.^[@yoi180080r32]^ This suggests that, for patients with cancer who are thought to be at higher risk of suicide, there may be scope to consider effective pain management options other than opioids,^[@yoi180080r33]^ transdermal administration routes, or to involve caregivers in medication administration and safeguarding.

Future Research {#H2-12-YOI180080}
---------------

Our study used a lower age limit of 18 years, and the numbers of suicides in patients with cancers younger than 18 years were low. We were therefore unable to investigate suicide risk in teenagers and young adults, among whom evidence is limited. Pooling data could help to address this gap, as could using statistical methods, such as the self-controlled case series approach, to identify the precise points at which suicide risk is elevated.^[@yoi180080r34]^ Further research could also consider hospital admissions for suicide attempts or the presence of preexisting or intercurrent psychiatric illness to support the identification of modifiable risk factors.

Conclusions {#H1-5-YOI180080}
===========

We found an elevated risk of suicide in patients with cancer, particularly in the first 6 months after diagnosis. Patients with mesothelioma, pancreatic, lung, esophageal, and stomach cancers had the highest risk. The increased risk of suicide persisted for 3 years after diagnosis, identifying a period during which cancer care pathways should pay attention to the psychological health needs of the patients. Suggested responses include addressing the underdiagnosis and undertreatment of depression and anxiety in patients with cancer, improving access to integrated psychological support for all patients with cancers, addressing modifiable risk factors, and restricting access to the means of lethal overdose.
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